Patient-reported outcomes (PROs) for symptoms and health-related quality of life (QoL) are reported here. The significant overall survival (OS) benefit observed with the addition of nintedanib to docetaxel therapy was achieved with no detrimental effect on patient self-reported QoL.

READ FULL ARTICLE Curated publisher From Mdlinx